Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Receivables (2016 - 2025)

Marimed has reported Receivables over the past 14 years, most recently at $9.1 million for Q4 2025.

  • Quarterly Receivables rose 4.26% to $9.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.1 million through Dec 2025, up 4.26% year-over-year, with the annual reading at $9.1 million for FY2025, 4.26% up from the prior year.
  • Receivables was $9.1 million for Q4 2025 at Marimed, up from $8.0 million in the prior quarter.
  • Over five years, Receivables peaked at $9.2 million in Q1 2025 and troughed at $4.4 million in Q1 2023.
  • The 5-year median for Receivables is $7.7 million (2024), against an average of $7.4 million.
  • The largest YoY upside for Receivables was 163.2% in 2021 against a maximum downside of 81.31% in 2021.
  • A 5-year view of Receivables shows it stood at $6.7 million in 2021, then skyrocketed by 31.85% to $8.8 million in 2022, then fell by 16.9% to $7.3 million in 2023, then increased by 19.69% to $8.7 million in 2024, then increased by 4.26% to $9.1 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Receivables are $9.1 million (Q4 2025), $8.0 million (Q3 2025), and $7.7 million (Q2 2025).